+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Chlamydia Infection Diagnostics and Therapeutics Market Report 2025

  • PDF Icon

    Report

  • 200 Pages
  • April 2025
  • Region: Global
  • The Business Research Company
  • ID: 6006893
This Chlamydia Infection Diagnostics and Therapeutics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The chlamydia infection diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $1.43 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to an increase in sexual activity, improving healthcare infrastructure, government initiatives, and funding, growing awareness and screening programs, and an increasing prevalence of chlamydia infections.

The chlamydia infection diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to awareness campaigns, high healthcare expenditure, rising incidence in young adults, regulatory approvals, expanding healthcare infrastructure, and a rising incidence of antibiotic resistance. Major trends in the forecast period include advancements in diagnostic technologies, the development of point-of-care tests, collaborations and partnerships, the development of effective treatment options, and technological advancement.

The increasing emphasis on preventive healthcare is anticipated to drive growth in the chlamydia infection diagnostics market. Preventive healthcare focuses on averting diseases through measures such as regular check-ups, vaccinations, and lifestyle changes, rather than addressing them post-occurrence. The aim is to lower healthcare expenses, enhance quality of life, and prevent chronic conditions through early detection and proactive care. This approach is crucial for chlamydia diagnostics, as it promotes early detection, education, and routine screening, which help in curbing the spread and complications of chlamydia infections. For example, in May 2023, the National Health Service (NHS) reported that around 23.02 million diagnostic tests were performed in March 2023, an increase of 223,100 tests from March 2022. Additionally, the number of patients awaiting a critical diagnostic test rose to 16.28 million in March 2023, up by 59,400 from the previous year. Thus, the heightened focus on preventive healthcare is a key factor driving the chlamydia infection diagnostics market.

Leading companies in the chlamydia infection diagnostics market are concentrating on developing advanced products, such as molecular point-of-care testing platforms, to maintain a competitive advantage. Molecular point-of-care (POC) testing platforms are diagnostic tools that detect and analyze specific nucleic acids (DNA or RNA) of pathogens directly at the patient care site. For instance, in March 2021, Binx Health Inc., a US-based health technology firm, announced that the US Food and Drug Administration (FDA) had granted a clinical laboratory improvement amendments (CLIA) waiver for their Binx IO system. This molecular point-of-care testing platform can deliver central laboratory-quality results within approximately 30 minutes for detecting chlamydia (CT) and gonorrhea (NG). The system had already received 510(k) clearance from the FDA for testing male and female samples in moderate and high-complexity settings.

In April 2022, Chiricahua Community Health Centers Inc. (CCHCI), a US-based healthcare service provider, partnered with The Body Agency Collective (TBAC) and Visby Medical, Inc. to enhance the diagnosis and treatment of sexually transmitted infections (STIs). This collaboration will utilize a PCR diagnostic device called the Sexual Health Click Test, capable of detecting three common and treatable STIs in women, gonorrhea, chlamydia, and trichomoniasis. TBAC is a US-based foundation that offers accessible sexual and reproductive health education, products, and services for women and girls. Visby Medical, Inc. is a US-based medical technology company focused on developing innovative diagnostic solutions to improve chlamydia diagnosis and treatment.

Major companies operating in the chlamydia infection diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Cepheid, Meridian Bioscience Inc., Sekisui Diagnostics, Copan Diagnostics.

North America was the largest region in the chlamydia infection diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia infection diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chlamydia infection diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chlamydia infection diagnostics involve methods and procedures used to detect and confirm the presence of Chlamydia trachomatis bacteria in individuals who may have a chlamydial infection. Accurate diagnostics are essential for proper diagnosis, treatment planning, and preventing further spread.

The primary diagnostic tests for chlamydia infection include culture tests, nucleic acid amplification tests (NAAT), direct fluorescent antibody tests, serology tests, among others. A culture test is a procedure where patient samples are cultured to identify microorganisms, which aids in diagnosing infections and determining the appropriate treatment. This test is applicable to various types of chlamydial infections, including genital, rectal, and ocular chlamydia. These tests are used in hospitals, specialty clinics, and diagnostic centers, serving different users such as diagnostic and therapeutic professionals.

The chlamydia infection diagnostics market research report is one of a series of new reports that provides chlamydia infection diagnostics market statistics, including chlamydia infection diagnostics industry global market size, regional shares, competitors with a chlamydia infection diagnostics market share, detailed chlamydia infection diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia infection diagnostics industry. This chlamydia infection diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chlamydia infection diagnostics market includes revenues earned by entities by providing services such as laboratory testing services, point-of-care testing, and consultation and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Chlamydia Infection Diagnostics and Therapeutics Market Characteristics3. Chlamydia Infection Diagnostics and Therapeutics Market Trends and Strategies4. Chlamydia Infection Diagnostics and Therapeutics Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
5. Global Chlamydia Infection Diagnostics and Therapeutics Growth Analysis and Strategic Analysis Framework
5.1. Global Chlamydia Infection Diagnostics and Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis of End Use Industries
5.3. Global Chlamydia Infection Diagnostics and Therapeutics Market Growth Rate Analysis
5.4. Global Chlamydia Infection Diagnostics and Therapeutics Historic Market Size and Growth, 2019-2024, Value ($ Billion)
5.5. Global Chlamydia Infection Diagnostics and Therapeutics Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
5.6. Global Chlamydia Infection Diagnostics and Therapeutics Total Addressable Market (TAM)
6. Chlamydia Infection Diagnostics and Therapeutics Market Segmentation
6.1. Global Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nucleic Acid Amplification Tests (NAATS)
  • Direct Fluorescent Tests
  • Macrolides
  • Quinolones
  • Sulfonamides
  • Tetracycline
  • Aminopenicillins
6.2. Global Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Genital Chlamydia Infection
  • Rectal Chlamydia Infection
  • Ocular Chlamydia Infection
6.3. Global Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Therapeutics
  • Hospital Pharmacies
  • Drugstores
  • Retail Pharmacies
  • Online Pharmacies
6.4. Global Chlamydia Infection Diagnostics and Therapeutics Market, Sub-Segmentation of Nucleic Acid Amplification Tests (NAATS), by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR-Based Tests
  • LAMP-Based Tests
6.5. Global Chlamydia Infection Diagnostics and Therapeutics Market, Sub-Segmentation of Direct Fluorescent Tests, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Direct Fluorescent Antibody Staining
  • Direct Fluorescent in-Situ Hybridization
6.6. Global Chlamydia Infection Diagnostics and Therapeutics Market, Sub-Segmentation of Macrolides, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Azithromycin
  • Erythromycin
6.7. Global Chlamydia Infection Diagnostics and Therapeutics Market, Sub-Segmentation of Quinolones, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ciprofloxacin
  • Ofloxacin
6.8. Global Chlamydia Infection Diagnostics and Therapeutics Market, Sub-Segmentation of Sulfonamides, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sulfamethoxazole
  • Trimethoprim-Sulfamethoxazole
6.9. Global Chlamydia Infection Diagnostics and Therapeutics Market, Sub-Segmentation of Tetracycline, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Doxycycline
  • Tetracycline
6.10. Global Chlamydia Infection Diagnostics and Therapeutics Market, Sub-Segmentation of Aminopenicillins, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Amoxicillin
  • Ampicillin
7. Chlamydia Infection Diagnostics and Therapeutics Market Regional and Country Analysis
7.1. Global Chlamydia Infection Diagnostics and Therapeutics Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Chlamydia Infection Diagnostics and Therapeutics Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Chlamydia Infection Diagnostics and Therapeutics Market
8.1. Asia-Pacific Chlamydia Infection Diagnostics and Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Chlamydia Infection Diagnostics and Therapeutics Market
9.1. China Chlamydia Infection Diagnostics and Therapeutics Market Overview
9.2. China Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Chlamydia Infection Diagnostics and Therapeutics Market
10.1. India Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Chlamydia Infection Diagnostics and Therapeutics Market
11.1. Japan Chlamydia Infection Diagnostics and Therapeutics Market Overview
11.2. Japan Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Chlamydia Infection Diagnostics and Therapeutics Market
12.1. Australia Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Chlamydia Infection Diagnostics and Therapeutics Market
13.1. Indonesia Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Chlamydia Infection Diagnostics and Therapeutics Market
14.1. South Korea Chlamydia Infection Diagnostics and Therapeutics Market Overview
14.2. South Korea Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Chlamydia Infection Diagnostics and Therapeutics Market
15.1. Western Europe Chlamydia Infection Diagnostics and Therapeutics Market Overview
15.2. Western Europe Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Chlamydia Infection Diagnostics and Therapeutics Market
16.1. UK Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Chlamydia Infection Diagnostics and Therapeutics Market
17.1. Germany Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Chlamydia Infection Diagnostics and Therapeutics Market
18.1. France Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Chlamydia Infection Diagnostics and Therapeutics Market
19.1. Italy Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Chlamydia Infection Diagnostics and Therapeutics Market
20.1. Spain Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Chlamydia Infection Diagnostics and Therapeutics Market
21.1. Eastern Europe Chlamydia Infection Diagnostics and Therapeutics Market Overview
21.2. Eastern Europe Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Chlamydia Infection Diagnostics and Therapeutics Market
22.1. Russia Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Chlamydia Infection Diagnostics and Therapeutics Market
23.1. North America Chlamydia Infection Diagnostics and Therapeutics Market Overview
23.2. North America Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Chlamydia Infection Diagnostics and Therapeutics Market
24.1. USA Chlamydia Infection Diagnostics and Therapeutics Market Overview
24.2. USA Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Chlamydia Infection Diagnostics and Therapeutics Market
25.1. Canada Chlamydia Infection Diagnostics and Therapeutics Market Overview
25.2. Canada Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Chlamydia Infection Diagnostics and Therapeutics Market
26.1. South America Chlamydia Infection Diagnostics and Therapeutics Market Overview
26.2. South America Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Chlamydia Infection Diagnostics and Therapeutics Market
27.1. Brazil Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Chlamydia Infection Diagnostics and Therapeutics Market
28.1. Middle East Chlamydia Infection Diagnostics and Therapeutics Market Overview
28.2. Middle East Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Chlamydia Infection Diagnostics and Therapeutics Market
29.1. Africa Chlamydia Infection Diagnostics and Therapeutics Market Overview
29.2. Africa Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Type of Infections, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Chlamydia Infection Diagnostics and Therapeutics Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Chlamydia Infection Diagnostics and Therapeutics Market Competitive Landscape and Company Profiles
30.1. Chlamydia Infection Diagnostics and Therapeutics Market Competitive Landscape
30.2. Chlamydia Infection Diagnostics and Therapeutics Market Company Profiles
30.2.1. F. Hoffman La-Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Sanofi S.a. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
31. Chlamydia Infection Diagnostics and Therapeutics Market Other Major and Innovative Companies
31.1. AstraZeneca
31.2. Abbott Laboratory
31.3. Novartis AG
31.4. GlaxoSmithKline PLC
31.5. Takeda Pharmaceutical
31.6. Danaher Corporation
31.7. Gilead Sciences
31.8. Siemens Healthineers
31.9. Becton Dickinson and Company
31.10. Accelerate Diagnostics
31.11. Hologic Inc.
31.12. Biomerieux
31.13. QuidelOrtho Corporation
31.14. Bio-Rad Laboratories Inc.
31.15. DiaSorin SpA
32. Global Chlamydia Infection Diagnostics and Therapeutics Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Chlamydia Infection Diagnostics and Therapeutics Market34. Recent Developments in the Chlamydia Infection Diagnostics and Therapeutics Market
35. Chlamydia Infection Diagnostics and Therapeutics Market High Potential Countries, Segments and Strategies
35.1 Chlamydia Infection Diagnostics and Therapeutics Market in 2029 - Countries Offering Most New Opportunities
35.2 Chlamydia Infection Diagnostics and Therapeutics Market in 2029 - Segments Offering Most New Opportunities
35.3 Chlamydia Infection Diagnostics and Therapeutics Market in 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Chlamydia Infection Diagnostics and Therapeutics Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chlamydia infection diagnostics and therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for chlamydia infection diagnostics and therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chlamydia infection diagnostics and therapeutics market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Nucleic Acid Amplification Tests (NAATS); Direct Fluorescent Tests; Macrolides; Quinolones; Sulfonamides; Tetracycline; Aminopenicillins
2) By Type of Infections: Genital Chlamydia Infection; Rectal Chlamydia Infection; Ocular Chlamydia Infection
3) By Application: Hospitals; Specialty Clinics; Diagnostic Centers Therapeutics; Hospital Pharmacies; Drugstores; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Nucleic Acid Amplification Tests (NAATS): PCR-Based Tests; LAMP-Based Tests
2) By Direct Fluorescent Tests: Direct Fluorescent Antibody Staining; Direct Fluorescent in-Situ Hybridization
3) By Macrolides: Azithromycin; Erythromycin
4) By Quinolones: Ciprofloxacin; Ofloxacin
5) By Sulfonamides: Sulfamethoxazole; Trimethoprim-Sulfamethoxazole
6) By Tetracycline: Doxycycline; Tetracycline
7) By Aminopenicillins: Amoxicillin; Ampicillin

Key Companies Mentioned: F. Hoffman La-Roche Ltd; Merck & Co. Inc.; AbbVie Inc; Sanofi S.a.; Bristol-Myers Squibb

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

The major companies featured in this Chlamydia Infection Diagnostics and Therapeutics market report include:
  • F. Hoffman La-Roche Ltd
  • Merck & Co. Inc.
  • AbbVie Inc
  • Sanofi S.A.
  • Bristol-Myers Squibb
  • AstraZeneca
  • Abbott Laboratory
  • Novartis AG
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical
  • Danaher Corporation
  • Gilead Sciences
  • Siemens Healthineers
  • Becton Dickinson and Company
  • Accelerate Diagnostics
  • Hologic Inc.
  • Biomerieux
  • QuidelOrtho Corporation
  • Bio-Rad Laboratories Inc.
  • DiaSorin SpA
  • Luminex Corporation
  • Meridian Bioscience
  • Trinity Biotech Plc
  • Copan Diagnostics
  • Hain Lifescience GmbH

Table Information